Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
820.00    -11.00 (-1.32%)
Bid:
816.00
Ask:
822.00
Spread: 6.00 (0.735%)
Market Cap: £774.61m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

10 Oct 2024 07:00

RNS Number : 6072H
Polar Capital Holdings PLC
10 October 2024
 

10 October 2024 Polar Capital Holdings plc

AuM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides a quarterly update of its unaudited statement of Assets under Management ("AuM").

 

 

Group AuM (unaudited)

 

Polar Capital reports that as at 30 September 2024 its AuM was £22.7bn compared to £21.9bn at the end of March 2024, an increase of 4%. During the six-month period, AuM increased by net inflows of £0.5bn and a £0.3bn increase related to market movement and fund performance.

 

AuM movement in six months to 30 September 2024

Open ended

Funds

(£m)

Investment

Trusts

(£m)

Segregated mandates

(£m)

Total

(£m)

AuM at 1 April 2024

15,988

5,088

816

21,892

Net flows

727

(102)

(153)

472

Market movement

and performance

225

94

4

323

Total AuM at

30 September 2024

16,940

5,080

667

22,687

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits due to the Group (after the deduction of staff interests) as a product of accrued performance fees in funds managed by the Group three months before the strike point of such performance fee receipts. The majority of the Group's performance fees crystallise in the second half of the financial year. There is no certainty that the fees will be sustained over the next quarter, as performance fees can be volatile.

 

Performance fees

net of staff allocations (All figures in £m)

Six months to

30 Sep 23

Year to

31 Mar 24

(year-end)

Six months to

30 Sep 24

Received

-

9.6

-

Accrued but not yet earned in funds with year ends on or before the financial year end

1.3

n/a

0.7*

Total net performance fee profits

1.3

9.6

0.7*

\* The figures have been reduced by £1.0m of net performance fee distributions that relate to prior accounting periods that are required to be deducted from this year's receipts for accounting purposes.

 

 

 

 

 

 

 

Gavin Rochussen, Chief Executive, commented:

 

"There has been continued demand for a broad range of our funds during the quarter. Those in net inflows included the Emerging Market Stars (both the UCITS and US-domiciled vehicles), Healthcare Opportunities, Japan Value, Artificial Intelligence and Biotechnology Funds, with combined net inflows of £393m across these funds in the quarter.

 

"AuM at the end of the six-month period was £22.7bn, an increase of 4% on the £21.9bn reported at the beginning of the financial year. This increase is the result of net inflows of £0.5bn and positive market movement and performance of £0.3bn.

 

"The more challenging market environment over the last quarter resulted in AuM declining from £23.5bn at the end of June 2024 primarily due to negative market movement and performance of £655m after the summer equity sell-off alongside net outflows of £172m driven by mandate redemptions.

 

"We were pleased to announce the launch of the US-domiciled Polar Capital International Small Company Fund with Dan Boston recruited as Lead Manager and Researcher. Dan brings 19 years' experience to his role and now heads our US-based and newly established Global Small Company team. The team take a 'research first' approach to seeking out wealth creating smaller companies with the ability to compound over the long-term and become industry leaders. International expansion remains a key part of our 'Growth with Diversification' strategy and this launch represents an important strategic milestone given Dan's proven track record.

 

"We remain confident that with our diverse range of differentiated, active specialist fund strategies we are well-positioned to perform for our clients and shareholders over the long term."

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)Samir Ayub (Chief Financial Officer)

+44 (0)20 7227 2700

 

Deutsche Numis - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

 

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

Oliver Jackson

 

+44 (0)20 3597 8680

 

Camarco - PR

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

 

+44 (0)20 3757 4980

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEAKENEAPLFFA
Date   Source Headline
19th Mar 202012:03 pmRNSPrice Monitoring Extension
12th Mar 20208:37 amRNSIssue of Equity
2nd Mar 20207:00 amRNSTotal Voting Rights
28th Feb 20204:41 pmRNSSecond Price Monitoring Extn
28th Feb 20204:36 pmRNSPrice Monitoring Extension
21st Feb 202011:51 amRNSForm 8.3 - Redde PLC
21st Feb 20209:59 amRNSIssue of Equity
20th Feb 20201:54 pmRNSForm 8.3 - Redde PLC
18th Feb 202011:14 amRNSForm 8.3 - Redde PLC
18th Feb 202010:28 amRNSChange of Auditor
17th Feb 20202:44 pmRNSForm 8.3 - Redde PLC
13th Feb 20202:37 pmRNSIssue of Equity
13th Feb 20207:00 amRNSTeam Acquisition
7th Feb 20201:09 pmRNSForm 8.3 - Redde PLC
6th Feb 20202:45 pmRNSForm 8.3 - Redde PLC
5th Feb 20202:33 pmRNSForm 8.3 - Redde PLC
3rd Feb 202011:14 amRNSBlock listing Interim Review
28th Jan 20201:06 pmRNSForm 8.3 - Redde PLC
22nd Jan 202011:13 amRNSForm 8.3 - Consort Medical PLC
21st Jan 20202:26 pmRNSForm 8.3 - Redde PLC
21st Jan 20202:12 pmRNSForm 8.3 - Consort Medical PLC
20th Jan 20202:01 pmRNSForm 8.3 - Consort Medical PLC
20th Jan 20201:37 pmRNSForm 8.3 - Redde PLC
17th Jan 202011:13 amRNSForm 8.3 - Redde PLC
17th Jan 202011:13 amRNSForm 8.3 - Consort Medical PLC
16th Jan 202012:28 pmRNSForm 8.3 - Redde PLC
16th Jan 202012:26 pmRNSForm 8.3 - Consort Medical PLC
15th Jan 202012:20 pmRNSForm 8.3 - Redde PLC
14th Jan 202012:00 pmRNSForm 8.3 - Redde PLC
13th Jan 20201:49 pmRNSForm 8.3 - Redde Plc
10th Jan 20201:09 pmRNSForm 8.3 - Redde Plc
9th Jan 20207:00 amRNSAuM Update
30th Dec 201912:35 pmRNSForm 8.3 - Redde PLC
24th Dec 201911:35 amRNSForm 8.3 - Redde PLC
23rd Dec 20193:24 pmRNSForm 8.3 - Redde PLC
20th Dec 201911:18 amRNSForm 8.3 - Redde PLC
19th Dec 20192:17 pmRNSForm 8.3 - Redde PLC
18th Dec 20191:42 pmRNSForm 8.3 - Consort Medical PLC
17th Dec 201910:58 amRNSForm 8.3 - Consort Medical Plc
17th Dec 20199:37 amRNSHolding(s) in Company
6th Dec 20191:09 pmRNSForm 8.3 - Consort Medical Plc
5th Dec 20192:24 pmRNSForm 8.3 - Consort Medical Plc
4th Dec 20191:22 pmRNSForm 8.3 - Consort Medical Plc
2nd Dec 20191:59 pmRNSForm 8.3 - Redde PLC
2nd Dec 20197:00 amRNSTotal Voting Rights
25th Nov 20197:00 amRNSUnaudited interim results
20th Nov 20194:40 pmRNSSecond Price Monitoring Extn
20th Nov 20194:35 pmRNSPrice Monitoring Extension
20th Nov 20191:52 pmRNSBlock Listing Application
20th Nov 20191:30 pmRNSCrystallisation of Business Unit & Issue of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.